Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, has announced its participation in the Centurion One Capital 2nd Annual Bahamas Summit.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, has announced its participation in the Centurion One Capital 2nd Annual Bahamas Summit. The event will take place at the Rosewood Baha Mar Hotel in Nassau, Bahamas on October 22-23, 2024.
Michael Redmond, President of Oragenics, is scheduled to deliver a corporate presentation and participate in a Q&A session on October 22, 2024, at 1:20 pm ET. This presentation offers an opportunity for investors and interested parties to gain insights into Oragenics' current projects and future plans in the field of brain health treatments.
Attendees can register for the event through a provided link, allowing them to participate in this significant gathering of industry professionals and potential investors in the pharmaceutical and biotechnology sectors.
Details
News Market Reaction – OGEN
The recorded move for OGEN in the trading session of this news was +0.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit to be held at the Rosewood Baha Mar Hotel on October 22-23, 2024, in Nassau, Bahamas. Michael Redmond, President of Oragenics, will participate in a corporate presentation and Q&A session on October 22, 2024 at 1:20 pm ET.
Details for the presentation are as follows:
Date: Tuesday, October 22, 2024
Time: 1:20 p.m. EDT
Presenter: Michael Redmond, President of Oragenics
Register for the event by clicking here.
About Oragenics:
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Investor Relations:
Rich Cockrell
CG Capital
404-736-3838
ogen@cg.capital
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.